Tirzepatide legal status: what's actually FDA-approved

Last updated 2026-07-27

Is tirzepatide legal to buy in the United States?

Yes, but only through specific, legal channels. Tirzepatide as a molecule is FDA-approved under two brand names: Zepbound for chronic weight management and Mounjaro for type 2 diabetes, both manufactured by Eli Lilly ^[1][2]. Buying either with a valid prescription from a licensed prescriber, filled at a licensed pharmacy, is completely legal. That's the simple part. What's murkier is compounded tirzepatide, the version made by compounding pharmacies rather than Lilly. That's legal only under specific conditions tied to federal drug compounding law (21 U.S.C. 353a for traditional pharmacies, 353b for outsourcing facilities), and those conditions got a lot tighter after the FDA removed tirzepatide from its drug shortage list in December 2024 ^[3]. The rules didn't disappear. They just narrowed considerably. If you're buying from an overseas website, a research-chemical vendor, or anyone selling "tirzepatide" without a prescription, that's not a legal purchase for human use, regardless of what the label says. The FDA has specifically warned about counterfeit and mislabeled tirzepatide sold this way ^[4]. For the specific intake steps a legitimate prescriber should walk you through, see Tirz Rx prescription requirements.

What's the difference between Zepbound, Mounjaro, and compounded tirzepatide?

Zepbound and Mounjaro are the identical active molecule (tirzepatide) at FDA-approved, quality-controlled doses, manufactured by Eli Lilly in an FDA-inspected facility. Zepbound is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition ^[1]. Mounjaro is approved for type 2 diabetes glycemic control ^[2]. Same drug, different indication on the label, different dose-titration schedule marketed for each. Compounded tirzepatide is not FDA-approved. A compounding pharmacy mixes the active pharmaceutical ingredient (often tirzepatide base or a salt form) into a custom preparation, sometimes with added B12 or other ingredients. The FDA has not evaluated these formulations for safety, efficacy, or sterility the way it evaluates Zepbound or Mounjaro. That doesn't automatically make it dangerous, but it does mean there's no batch-level FDA oversight, and the agency has said as much directly: compounded drugs "are not FDA-approved," and the agency "does not verify the safety or effectiveness of compounded drugs" ^[5]. | | Zepbound | Mounjaro | Compounded tirzepatide |

Is compounded tirzepatide still legal after the shortage ended?

Mostly not, or only in narrow circumstances. The FDA added tirzepatide to its drug shortage list in 2022 as demand outstripped Lilly's supply, which is what opened the door for compounding pharmacies to legally produce copies under the shortage exemptions in federal compounding law. That exemption ended when the FDA determined the tirzepatide shortage was resolved, effective December 19, 2024 ^[3]. After that date, mass compounding of tirzepatide as a shortage workaround is no longer permitted under the same legal basis. Compounding can still happen legally, but only under the standard, narrower rules: a 503A pharmacy can compound for an individual patient with a valid prescription when there's a legitimate medical reason (a documented allergy to an inactive ingredient in the branded product, a need for a different strength or route, for example), and 503B outsourcing facilities can compound in larger batches under separate FDA registration, but not simply because a compounder can sell it cheaper. A few compounders pushed back through litigation arguing tirzepatide isn't a true "essentially a copy" of Zepbound because of dose or delivery differences, and some products remain on the market through that legal gray zone. That's an active, contested area, not a settled green light. If a seller can't explain why your prescription meets one of these narrow exceptions, that's a real red flag, not a technicality.

Do I need a prescription for tirzepatide?

Yes. Tirzepatide, in any FDA-approved or legally compounded form, is a prescription-only medication in the United States. There's no over-the-counter version, and no legitimate telehealth pathway skips the prescribing step entirely, even if the online process feels quick. A legitimate prescription requires a licensed prescriber (physician, nurse practitioner, or physician assistant depending on state scope-of-practice rules) to review your health history, sometimes via telehealth, and determine whether tirzepatide is appropriate for you. That usually means checking BMI, relevant labs, personal and family history (especially thyroid cancer history, more on that below), and current medications for interaction risk. For more on what that intake actually looks like, see Tirz Rx prescription requirements. And for how dosing gets managed once you're cleared to start, Tirz Rx injection sites covers the practical side of administration.

What does the FDA-approval evidence for tirzepatide actually show?

It's genuinely strong, which is part of why tirzepatide has become the default GLP-1/GIP option for a lot of prescribers. The Mounjaro approval rested on the SURPASS trial program. SURPASS-2 (NCT03987919), a 40-week head-to-head against semaglutide 1 mg in adults with type 2 diabetes, found tirzepatide at 15 mg produced an HbA1c reduction of 2.30 percentage points versus 1.86 for semaglutide, and mean weight loss of 11.2 kg versus 5.7 kg ^[6]. Zepbound's approval rested on the SURMOUNT program. SURMOUNT-1 (NCT04184622), a 72-week trial in adults with obesity or overweight without diabetes, found the highest dose (15 mg) produced average weight loss of 20.9% of body weight versus 3.1% for placebo ^[7]. That's a genuinely large effect size for a pharmacologic obesity treatment, and it's the headline number that drove Zepbound's 2023 approval. These are the trials underlying the FDA-approved products specifically. Compounded tirzepatide has not been separately trialed; it relies entirely on the assumption that the compounded formulation behaves like the studied molecule, which depends on purity, correct salt form, and accurate dosing, none of which is independently verified the way Lilly's manufacturing is.

What are the real side effects and safety warnings for tirzepatide?

The most common effects are gastrointestinal: nausea, diarrhea, constipation, and vomiting, reported in a substantial share of trial participants across both the SURPASS and SURMOUNT programs, generally highest during dose escalation ^[1][2]. These usually ease as the body adjusts, but they're not rare or minor for a meaningful subset of users, and they're the leading reason people discontinue. Zepbound and Mounjaro both carry a boxed warning, the FDA's most serious label warning, for risk of thyroid C-cell tumors, based on findings in rodent studies. The labeling states tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[1][2]. It's not confirmed that this risk translates to humans, but the FDA required the warning based on the animal data, and it's a hard contraindication, not a soft caution. Other documented risks include acute pancreatitis, gallbladder disease (including gallstones), acute kidney injury (often secondary to dehydration from GI side effects), hypoglycemia when combined with insulin or sulfonylureas, and hypersensitivity reactions. Anyone with a history of pancreatitis, gallbladder disease, or severe GI conditions should discuss that specifically with a prescriber before starting. None of this makes tirzepatide unusually dangerous by pharmaceutical standards, but it's a real drug with a real side-effect burden, not a lifestyle supplement, and it deserves to be treated that way.

How do I know if a tirzepatide seller is operating legally?

A few concrete checks. First, is a licensed prescriber actually involved, with a real intake process (medical history, current medications, in most states some form of clinical review beyond a checkbox form)? Second, is the pharmacy filling it named, licensed, and traceable, ideally one you can verify through your state board of pharmacy? Third, is the product labeled clearly as tirzepatide (or as a specific compounded formulation) rather than marketed under vague terms designed to dodge scrutiny? Fourth, does the seller make claims that sound too aggressive relative to the trial data, like guaranteed rapid loss numbers beyond what SURMOUNT-1 or SURPASS-2 actually showed? The FDA has repeatedly flagged counterfeit tirzepatide products, including some seized that turned out to contain the wrong salt form or no active ingredient at all ^[4]. If a site sells vials with no prescription requirement, ships from unclear jurisdictions, or won't name the dispensing pharmacy, that's not a minor process quibble. That's the actual signal of an illegal or unsafe operation. For a rundown on how to check a specific product's approval status, see is Tirz Rx FDA approved.

Is Tirzepatide itself FDA-approved or a manufacturer?

Tirz Rx is not a drug manufacturer and does not compound tirzepatide itself. It functions as a provider-reviewed resource and access point that connects patients to licensed prescribers and pharmacy partners who dispense either FDA-approved Zepbound/Mounjaro or, where clinically appropriate, compounded tirzepatide through a licensed pharmacy. The FDA approval question applies to the drug product, not to a platform. Zepbound and Mounjaro are FDA-approved; any compounded product dispensed through a partner pharmacy is subject to the compounding rules described above, not to a separate FDA approval, because compounded drugs by definition don't go through the New Drug Application process ^[5]. If you want the detailed version of that distinction, including how to verify a given prescription pathway, is Tirz Rx FDA approved covers it directly.

What does a legitimate prescription and dosing process actually look like?

Tirzepatide dosing under both Zepbound and Mounjaro labeling starts low and escalates on a fixed schedule to limit GI side effects. The standard starting dose is 2.5 mg once weekly by subcutaneous injection for four weeks, then stepping up in 2.5 mg increments roughly every four weeks as tolerated, up to a maximum of 15 mg weekly ^[1][2]. That titration schedule is exactly what SURMOUNT-1 and SURPASS-2 used, which is part of why real-world results tend to track the trial data reasonably well when the protocol is followed. A legitimate provider will follow that schedule or a close clinical variant, not push you straight to a high dose to chase faster results. They should also review injection technique and site rotation, since subcutaneous administration technique affects both absorption and injection-site reactions. For the practical side of that, Tirz Rx injection sites covers rotation and technique in more detail. Anyone offering tirzepatide without any dose titration plan, or without ever asking about your medical history before shipping, isn't running a legitimate clinical process, regardless of what the marketing copy says.

What should I actually do given all this?

If cost isn't the deciding factor, Zepbound or Mounjaro through insurance or a manufacturer savings program is the cleanest legal and quality path, since it's the exact formulation and dosing studied in SURMOUNT-1 and SURPASS-2. If cost is the deciding factor, and it often is given list prices in the $1,000+ per month range before insurance, a compounded option through a licensed pharmacy with a real prescribing process is legal in narrower circumstances than it was during the shortage, and worth vetting carefully rather than assumed to be equivalent by default. What I wouldn't do: buy from a site with no prescriber involvement, no named dispensing pharmacy, or claims that read like a supplement ad rather than a medical treatment. That's where the counterfeit and quality-control risk actually concentrates, and it's the exact pattern the FDA has warned about ^[4].

Frequently asked questions

Is tirzepatide legal in the US without a prescription?

No. Tirzepatide is prescription-only in every legal form, whether it's branded Zepbound, branded Mounjaro, or compounded through a licensed pharmacy. Any seller offering it without a prescriber's involvement is operating outside the legal framework the FDA and state pharmacy boards require, regardless of how the product is labeled or marketed.

Is compounded tirzepatide legal in 2025?

It's legal only in narrower cases now. The FDA's official shortage designation for tirzepatide ended December 19, 2024, which closed the broad shortage-based exemption that let compounding pharmacies produce it freely. Compounding can still be legal for individual patients with a documented clinical need under 21 U.S.C. 353a, but blanket compounding as a cheaper alternative is no longer the same legal basis it was in 2023 to 2024.

What is the difference between Zepbound and Mounjaro?

Same active molecule, tirzepatide, made by Eli Lilly. Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. Mounjaro is FDA-approved for type 2 diabetes glycemic control. Dosing schedules and marketing differ by indication, but the drug itself is identical.

Does the FDA approve compounded tirzepatide?

No. The FDA does not approve compounded drugs at all, branded or otherwise, because compounding falls outside the New Drug Application process. The agency has stated it "does not verify the safety or effectiveness of compounded drugs," so compounded tirzepatide operates under pharmacy compounding law, not FDA drug approval, even when legally dispensed.

What trials support tirzepatide's FDA approval?

Mounjaro's approval rests on the SURPASS program, including SURPASS-2 (NCT03987919), which showed larger HbA1c and weight reductions than semaglutide 1 mg over 40 weeks. Zepbound's approval rests on SURMOUNT-1 (NCT04184622), a 72-week trial showing 20.9% average body weight loss at the 15 mg dose versus 3.1% for placebo.

What is the boxed warning on tirzepatide for?

Both Zepbound and Mounjaro carry a boxed warning for risk of thyroid C-cell tumors, based on rodent studies, not confirmed human data. The drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a hard contraindication, not a minor caution.

Can I get in legal trouble for buying tirzepatide online?

Individual buyers generally aren't prosecuted the way sellers are, but purchasing from unlicensed overseas or research-chemical sites carries real health risk from counterfeit or mislabeled product, and any product seized at import can be confiscated. The legal exposure concentrates on unlicensed sellers and pharmacies operating outside compounding law, not typically on patients.

Is tirzepatide the same as semaglutide?

No. Tirzepatide (Zepbound, Mounjaro) activates both GLP-1 and GIP receptors; semaglutide (Wegovy, Ozempic) activates GLP-1 only. Head-to-head, SURPASS-2 found tirzepatide 15 mg produced greater HbA1c reduction (2.30 vs 1.86 percentage points) and more weight loss (11.2 kg vs 5.7 kg) than semaglutide 1 mg over 40 weeks in adults with type 2 diabetes.

How much does legal tirzepatide cost without insurance?

Eli Lilly's list price for Zepbound and Mounjaro has run in the range of roughly $1,000 to $1,300 per month without insurance, though savings card programs and Lilly's direct-to-consumer channels have periodically lowered effective cost for some patients. Compounded versions through licensed pharmacies are typically cheaper but carry the quality caveats described above.

What side effects should I expect starting tirzepatide?

Nausea, diarrhea, constipation, and vomiting are the most commonly reported effects in both the SURPASS and SURMOUNT trial programs, usually worse during the first few weeks of dose escalation. Most people find these ease over time. Report severe abdominal pain, since it can signal pancreatitis or gallbladder issues, both documented risks with tirzepatide.

Who should not take tirzepatide?

Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not take it; this is an FDA-required contraindication. People with a history of pancreatitis, severe gastrointestinal disease, or gallbladder disease should discuss those risks specifically with a prescriber, since tirzepatide's labeling documents elevated risk in these areas.

How is tirzepatide dosed under FDA labeling?

Both Zepbound and Mounjaro start at 2.5 mg once weekly by subcutaneous injection for four weeks, then increase in 2.5 mg increments roughly every four weeks as tolerated, up to a maximum of 15 mg weekly. This titration schedule matches what was used in the SURMOUNT-1 and SURPASS-2 trials.

Sources

1. FDA, Zepbound prescribing information: Zepbound's FDA-approved indication, boxed warning for thyroid C-cell tumors, MTC/MEN2 contraindication, dosing schedule, and common GI side effects
2. FDA, Mounjaro prescribing information: Mounjaro's FDA-approved indication for type 2 diabetes, boxed warning, contraindications, and dosing schedule
3. FDA, Human Drug Compounding: FDA states compounded drugs are not FDA-approved and the agency does not verify their safety or effectiveness
4. ClinicalTrials.gov, SURPASS-2 (NCT03987919): SURPASS-2 trial design and outcomes comparing tirzepatide to semaglutide 1 mg in type 2 diabetes
5. ClinicalTrials.gov, SURMOUNT-1 (NCT04184622): SURMOUNT-1 trial design and 72-week weight loss outcomes underlying Zepbound's approval
6. Cornell Legal Information Institute, 21 U.S.C. 353a: Federal statute governing traditional (503A) pharmacy compounding conditions
7. Cornell Legal Information Institute, 21 U.S.C. 353b: Federal statute governing outsourcing facility (503B) compounding conditions